Polyethylene Glycol 3350 ( DrugBank: Polyethylene glycol, Polyethylene glycol 3350 )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
96	Crohn disease	2
299	Cystic fibrosis	1

96. Crohn disease

---

Clinical trials : 2,442 /  Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03476317 (ClinicalTrials.gov)	July 12, 2018	8/1/2018	Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease	An Open-Label Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease	Crohn Disease	Drug: Vancomycin;Drug: Neomycin;Drug: Ciprofloxacin;Drug: Polyethylene Glycol 3350;Drug: Fluconazole	Children's Hospital of Philadelphia	University of Pennsylvania;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	Completed	6 Years	N/A	All	10	Phase 2	United States
2	NCT02765256 (ClinicalTrials.gov)	August 2016	2/5/2016	Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease	Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease	Crohn's Disease	Drug: Fluconazole;Drug: Vancomycin;Drug: Neomycin;Drug: Ciprofloxacin;Drug: Polyethylene Glycol 3350;Drug: Promethazine;Drug: Fluconazole placebo	University of Pennsylvania	Children's Hospital of Philadelphia;Crohn's and Colitis Foundation	Completed	18 Years	75 Years	All	8	Phase 2	United States

299. Cystic fibrosis

---

Clinical trials : 1,695 /  Drugs : 1,527 - (DrugBank : 268) / Drug target genes : 111 - Drug target pathways : 174

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04210427 (ClinicalTrials.gov)	December 12, 2019	18/12/2019	Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit	Cystic Fibrosis and Gut Dysmotility: The Effect of Polyethylene Glycol (PEG) on Intestinal Transit	Cystic Fibrosis Gastrointestinal Disease	Drug: Polyethylene Glycol 3350;Device: SmartPill Motility System & PillCam Patency Capsule	St. Louis University	NULL	Recruiting	18 Years	40 Years	All	15	Phase 4	United States